Lynparza on cusp of approval for advanced ovarian cancerBreast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type Share XLynparza on cusp of approval for advanced ovarian cancerhttps://pharmaphorum.com/news/lynparza-on-cusp-of-approval-for-advanced-ovarian-cancer/
Merck and Pfizer stop third Bavencio ovarian cancer trialMerck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share XMerck and Pfizer stop third Bavencio ovarian cancer trialhttps://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
AZ/Merck & Co get new US use for ovarian cancer drugAfter several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for Share XAZ/Merck & Co get new US use for ovarian cancer drughttps://pharmaphorum.com/news/astrazeneca-merck-lynparza-roxadustat/
US regulator grants fast review for AZ ovarian cancer drugThe US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza Share XUS regulator grants fast review for AZ ovarian cancer drughttps://pharmaphorum.com/news/us-regulator-grants-fast-review-for-az-ovarian-cancer-drug/
ESMO round-up: Big win for AstraZeneca in ovarian cancer, and moreSeveral drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich. Share XESMO round-up: Big win for AstraZeneca in ovarian cancer, and morehttps://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/
AZ/Merck & Co’s Lynparza scores huge ovarian cancer winAstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in Share XAZ/Merck & Co’s Lynparza scores huge ovarian cancer winhttps://pharmaphorum.com/news/az-merck-cos-lynparza-scores-huge-ovarian-cancer-win/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Chinese pharma market primed for growth after sweeping reformsChina has carved itself a place as a major player in the pharma industry due to the number Share XChinese pharma market primed for growth after sweeping reformshttps://pharmaphorum.com/r-d/views-analysis-r-d/chinese-pharma-market/
J&J hopes to overturn $4.69bn compensation billJohnson & Johnson lawyers are gearing up to appeal a court ruling, which rewarded billions to 22 women Share XJ&J hopes to overturn $4.69bn compensation billhttps://pharmaphorum.com/news/jj-hopes-to-overturn-4-69bn-compensation-bill/
